找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Handbook of Antimicrobial Resistance; Matthias Gotte (Editor-in-chief),Albert Berghuis,D Reference work 2017 Springer Science+Business Med

[復(fù)制鏈接]
樓主: 斷頭臺(tái)
31#
發(fā)表于 2025-3-26 21:48:40 | 只看該作者
HBV Therapy and the Problem of Drug Resistancee risk of liver disease progression, including cirrhosis, hepatic failure, and hepatocellular carcinoma. Nucleos(t)ide analogue monotherapy is commonly used as first-line therapy, and most patients will require long-term antiviral therapy. As for all direct-acting antiviral agents, the emergence of
32#
發(fā)表于 2025-3-27 02:05:31 | 只看該作者
Protease Inhibitor ResistanceV infection, allowing for viral elimination in the majority of treated patients. The first two drugs to be approved for the treatment of HCV genotype 1 infection were the HCV NS3/4A protease inhibitors telaprevir and boceprevir. However, their administration in combination with pegylated interferon
33#
發(fā)表于 2025-3-27 08:27:47 | 只看該作者
34#
發(fā)表于 2025-3-27 09:55:50 | 只看該作者
Resistance to Cyclophilin Inhibitorst accomplished by combining several drugs with potent antiviral activity across multiple genotypes, with each possessing a high barrier to resistance, different mechanisms of action, and no cross-resistance. A novel class of anti-HCV agents that have shown great promise in HCV patients – the cycloph
35#
發(fā)表于 2025-3-27 15:07:25 | 只看該作者
Antiviral Drug Resistance in Herpesviruses) and varicella-zoster virus (VZV) infections. The modest activity of ACV against human cytomegalovirus (HCMV) has prompted the development of another nucleoside analogue, ganciclovir (GCV), for the management of systemic and organ-specific HCMV diseases. Second-line agents such as the pyrophosphate
36#
發(fā)表于 2025-3-27 18:02:33 | 只看該作者
Quasispecies and Drug Resistance features of RNA viral quasispecies such as internal interactions within mutant spectra and the effect of population size and bottleneck events as they affect the frequency of inhibitor-escape mutants. Genetic barriers to resistance and fitness cost of specific amino acid substitutions involved in r
37#
發(fā)表于 2025-3-27 23:16:42 | 只看該作者
38#
發(fā)表于 2025-3-28 06:03:57 | 只看該作者
The Mechanisms of Resistance to β-Lactam Antibiotics antibacterials is the β-lactams that target the transpeptidase enzymes, which are responsible for cross-linking the peptidoglycan cell wall. There are over 34 FDA-approved β-lactams which together constitute ~50 % of all antibiotic prescriptions worldwide (Tahlan K and Jensen SE, J Antibiot (Tokyo)
39#
發(fā)表于 2025-3-28 09:28:01 | 只看該作者
Antibiotic Resistance and Tolerance in Bacterial Biofilmss are ubiquitous in the natural and industrial environment, their importance in human infections has only been fully recognized in the past few decades. Biofilm-associated bacteria typically cause subacute and chronic infections. Many bacterial pathogens, such as . readily form biofilms, and . which
40#
發(fā)表于 2025-3-28 14:01:37 | 只看該作者
Strategies for Circumventing Bacterial Resistance Mechanismsmised but is now found both in and out the boundaries of the hospital. Preserving the efficacy of the antibacterials we have, in order to secure the time needed to discover and develop new antibacterials, will require abrupt change: in the way antibacterials are dispensed and disposed, in the criter
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-9 02:49
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
图木舒克市| 长宁区| 电白县| 临江市| 青神县| 陆川县| 抚顺市| 呼图壁县| 宁乡县| 峨边| 永安市| 云南省| 右玉县| 潼南县| 平谷区| 仙桃市| 深水埗区| 浦东新区| 从化市| 阜阳市| 常熟市| 永丰县| 东海县| 临安市| 苏尼特右旗| 静安区| 察雅县| 蓬莱市| 庆元县| 通化县| 余庆县| 临夏县| 宜宾县| 沈阳市| 博客| 嵩明县| 营口市| 湘潭市| 泾川县| 桃源县| 土默特左旗|